lisocabtagene maraleucel
bms
['transform,(-transformi),(-transforme),(-transforma),(-transforms),(-transform1),(-transform 1),(-transform-1),(-transform2),(-transform 2),(-transform-2)', 'liso-cel']
#ash22
abstract 655 - jeremy s. abramson et al. with longer follow-up, results of the transform study confirm that liso-cel can be considered as the preferred second-line treatment for patients with primary refractory or early relapsed lbcl. 
Hematologist at Saint Antoine Hospital, Paris, France @Sorbonne_Univ_ @APHP. @JACIE_EBMT National Representative. #BMTsm #LYMsm #CARTcell #CardioOnc #QoL